How this Wetherby drug developer is looking to speed up testing for the virus

The Wetherby-based firm will collaborate with life sciences firm Cytiva to create a test that can diagnose the infection within minutes using a respiratory sample such as saliva.

Dr Alastair Smith, CEO of Avacta, said: "I am delighted that we have established this collaboration with Cytiva to develop, manufacture and commercialise a rapid test for Covid-19 infection.

"Importantly the test will indicate if a person has the virus now, whether they are showing symptoms or not, and will do so in minutes, in-situ with no need for laboratory equipment.

"Unfortunately, many millions of people around the world will ultimately become infected and it is likely to be an annual occurrence. There is a clear and urgent need for a test that can be carried out quickly in the community to limit the spread of the virus and track its progress."

The World Health Organisation recently highlighted the need for the development of rapid tests to quickly diagnose Covid-19 at point-of-care to assist in limiting and tracking infections.

Existing tests are not suitable for screening large numbers of people for the infection as they are laboratory based and it can take up to several days to get the results.

Avacta and Cytiva will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the infection.

Dr Smith said: "We have demonstrated before in the case of the Zika virus that the Affimer platform can very quickly provide highly specific reagents in response to an outbreak of an infectious disease.

"Our partnership with Cytiva means that we now have a global technology partner for a Covid-19 diagnostic which is essential if a practical and commercial solution is to be provided to governments and healthcare providers around the world promptly.

"Hundreds of millions of tests will be needed for population screening and we will be working hard to deliver an Affimer based solution on Cytiva's platform, and potentially on the platforms of other partners with whom we are in active discussion, as soon as possible.

"We are aiming to have developed Affimer reagents for a Covid-19 test by the end of May that can be transferred to Cytiva and potentially to other global diagnostic manufacturers to implement in a test strip."

Editor’s note: first and foremost - and rarely have I written down these words with more sincerity - I hope this finds you well.

Almost certainly you are here because you value the quality and the integrity of the journalism produced by The Yorkshire Post’s journalists - almost all of which live alongside you in Yorkshire, spending the wages they earn with Yorkshire businesses - who last year took this title to the industry watchdog’s Most Trusted Newspaper in Britain accolade.

And that is why I must make an urgent request of you: as advertising revenue declines, your support becomes evermore crucial to the maintenance of the journalistic standards expected of The Yorkshire Post. If you can, safely, please buy a paper or take up a subscription. We want to continue to make you proud of Yorkshire’s National Newspaper but we are going to need your help.

Postal subscription copies can be ordered by calling 0330 4030066 or by emailing [email protected]. Vouchers, to be exchanged at retail sales outlets - our newsagents need you, too - can be subscribed to by contacting subscriptions on 0330 1235950 or by visiting www.localsubsplus.co.uk where you should select The Yorkshire Post from the list of titles available.

If you want to help right now, download our tablet app from the App / Play Stores. Every contribution you make helps to provide this county with the best regional journalism in the country.

Sincerely. Thank you.

James Mitchinson

Editor